Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedA site-wide notice about government funding lapse and NIH operations was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check13 days agoChange DetectedAdded a Show glossary option, added Last Update Submitted that Met QC Criteria, added No FEAR Act Data, and updated Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, removed No FEAR Act data, and removed Revision: v3.3.4.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed; there are no changes to the study details, eligibility criteria, locations, or primary/secondary outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedLocations section now consolidates and lists participating sites by state (Arizona, California, Florida, Iowa, Massachusetts, Minnesota, Mississippi, New York, North Carolina, Ohio, Oregon, Rhode Island, Tennessee, Texas, Virginia). The HHS Vulnerability Disclosure link was removed and the page revision is updated to v3.3.3.SummaryDifference1%

- Check70 days agoChange DetectedFooter revision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check77 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and introduced a revision tag labeled v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.